You are here
There is a growing discussion in Australia and internationally about the need to increase focus on delivering value-based health care with a focus on patient outcomes and experience.
IHPA’s Pricing Guidelines and the National Health Reform Agreement include provisions for IHPA to consider the impact on its work of evidence‑based, effective new technologies and innovations in models of health care.
IHPA requires accurate activity, cost and expenditure data from jurisdictions on a timely basis in order to perform its core determinative functions. This data plan sets out IHPA's seventh rolling Three Year Data Plan, covering the period 2019-20 to 2021-22. The Three Year Data Plan specifies the data requirements and timelines that IHPA will use to collect data over the next three years.
The Independent Hospital Pricing Authority (IHPA) is currently developing a new classification for non-admitted care - the Australian Non-Admitted Care Classification (ANACC) - in response to the recommendations of public consultations in 2013 and 2014 on non-admitted care classification.
Bundled pricing is where a single price covers a full package of care over a defined period of time, spanning multiple events and settings of care. The intention is for resources and funding to be easier for hospitals to manage, to allow financial flexibility to encourage improved models of care or greater standardisation of evidence-based care, and drive better service delivery in the long run which should lead to better patient outcomes and lower costs.
IHPA requires accurate activity, cost and expenditure data from jurisdictions on a timely basis in order to perform its core determinative functions.
This data plan sets out IHPA’s fifth rolling Three Year Data Plan, covering the period
2017-18 to 2019-20.
The data plans of IHPA and the Administrator have been harmonised to provide a standard document structure and an appendix listing shared data collection.
The non-admitted study was comprehensive across a range of settings (e.g. outpatients, community and satellite clinics). Similarly all service streams were included regardless of funding source. This ensured that all services were accounted for and costed appropriately providing an accurate cost of delivering multiple services across multiple settings (e.g. overhead costs are apportioned across all patients).
The costing study on home delivered dialysis was undertaken in 2014. The purpose of the study was to collate and compare the range of costing studies and economic evaluations that have been carried out on these services over the past decade.
The report identifies two key studies - NSW Dialysis Costing Study, conducted in 2008, and Queensland Health Renal Replacement Therapy Costing Study, conducted in 2008 - which are useful in estimating the current costs of home-based dialysis.
PwC and its sub-contractor The Independent Hospital Pricing Authority (IHPA) engaged PwC and its sub-contractor SyRis Consulting to undertake a review and costing study of Australian radiotherapy services. The study was commissioned to determine the reliability of radiotherapy cost data due to its role in the development of associated price weights in both admitted and non-admitted settings.